Related Experiment Video

Updated: Aug 7, 2026

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans
12:57

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans

Published on: January 8, 2015

Delineating common molecular mechanisms in Alzheimer's and prion diseases

Kevin J Barnham1, Roberto Cappai, Konrad Beyreuther

  • 1Department of Pathology, and Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, VIC 3010, Australia.

Trends in Biochemical Sciences
|July 6, 2006
PubMed

Insights

Prion diseases and Alzheimer's disease may share therapeutic strategies due to similarities between prion protein (PrP) and amyloid-beta peptide (Abeta). Both involve beta-rich protein structures and potential metal ion toxicity mechanisms.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pathology

Background:

  • Prion diseases are linked to beta-rich prion protein (PrP) conformers, but their structure remains unclear.
  • Alzheimer's disease pathogenesis involves amyloid-beta peptide (Abeta), a toxic fragment of amyloid precursor protein.
  • Abeta toxicity may stem from metal ion (e.g., copper) coordination, reactive oxygen species generation, and lipid bilayer interactions.

Purpose of the Study:

  • To explore potential shared therapeutic strategies for prion diseases and Alzheimer's disease.
  • To highlight sequence and chemical similarities between PrP and Abeta.

Main Methods:

  • Comparative analysis of structural and mechanistic properties of PrP and Abeta.
  • Review of existing literature on prion disease and Alzheimer's disease pathogenesis.

Main Results:

  • Evidence suggests prion diseases involve beta-rich PrP conformers.
  • Abeta is implicated in Alzheimer's disease toxicity, potentially via metal ion interactions and oxidative stress.
  • Significant sequence and chemical similarities exist between PrP and Abeta.

Conclusions:

  • The shared characteristics between PrP and Abeta suggest that therapeutic approaches effective for one disease may be applicable to the other.
  • Further research into these similarities could yield novel treatments for both neurodegenerative conditions.

More Related Videos

Monitoring Cell-to-cell Transmission of Prion-like Protein Aggregates in Drosophila Melanogaster10:26

Monitoring Cell-to-cell Transmission of Prion-like Protein Aggregates in Drosophila Melanogaster

Published on: March 12, 2018

Sensitive Detection of Proteopathic Seeding Activity with FRET Flow Cytometry12:31

Sensitive Detection of Proteopathic Seeding Activity with FRET Flow Cytometry

Published on: December 8, 2015

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...